PRA International (Reston, VA, www.prainternational.com) has completed the acquisition of Pharma Bio-Research (Zuidlaren, The Netherlands), an early-phase clinical development and bioanalytical company.
PRA International (Reston, VA, www.prainternational.com) has completed the acquisition of Pharma Bio-Research (Zuidlaren, The Netherlands), an early-phase clinical development and bioanalytical company. Plans for PRA International to acquire Pharma Bio-Research were originally announced on June 19. The acquisition, valued at 84.6 million Euros, provides PRA International with early-phase development and bioanalytical laboratory facilities in Europe. PRA also expects to draw on Pharma Bio-Research’s expertise to establish drug development laboratory facilities in the US for biotech and pharmaceutical clients.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.